

Please type a plus sign (+) inside this box []

+

08-08-07

IFW

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/737,245
Filing Date	December 15, 2003
First Named Inventor	Palani Balu
Group/Art Unit	1656
Examiner Name	Kam, Chih Min

Total Number of Pages in This Submission

Attorney Docket Number 44368-0005 C1

ENCLOSURES (check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Version With Markings Showing Changes
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input checked="" type="checkbox"/> Information Disclosure Statement w/ 74 references
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53
<input type="checkbox"/> Copy of Notice | <input type="checkbox"/> Copy of an Assignment
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):
<input checked="" type="checkbox"/> RETURN STAMPED POSTCARD PTO -1449; 74 References |
|---|---|--|

Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 44368-0005 C1**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual name	HELLER EHRMAN LLP	JEFFERY P. BERNHARDT (Reg. No. 54,997)
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature	<i>J.P. Bernhardt</i>	
Date	August 6, 2007	Customer Number: 25213

CERTIFICATE OF EXPRESS MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **MAIL STOP Amendment**, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: **August 6, 2007**.Express Mail Label **EL 993 631 868 US**

Typed or printed name	Rossetti Saena		
Signature	<i>Rossetti Saena</i>	Date	August 6, 2007

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ___, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT

Attorney Docket No. 44368-0005 C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Palani Balu)	
)	Art Unit: 1656
Application No.: 10/737,245)	
)	Examiner: Kam, Chih Min
Filed: December 15, 2003)	
)	
Title Peptide Dimers as Agonists of the Erythropoietin)	
(EPO) Receptor, and Associated Methods of)	
Synthesis and Use)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language and all additional publications other than U.S. patents and U.S. patent application publications or is identified, with an asterisk (*), as having been previously cited in priority U.S. Patent Application No.: 09/449,064, filed: November 24, 1999, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application,

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 44368-0005 C1).


Respectfully submitted,

HELLER EHRMAN LLP

By: J.P. Bernhardt
Jeffery P. Bernhardt, Reg. No. 54,997

Dated: August 6, 2007

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213



INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 44368-0005 C1	SERIAL NO. 10/737,245
	APPLICANT Palani Balu	
	FILING DATE 12/15/2003	GROUP 1656

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
*	4,179,337	12/18/1979	Davis, et al			
*	4,301,144	11/17/1981	Iwoshita, et al.			
*	4,496,689	01/29/1985	Mitra			
*	4,612,132	09/16/1986	Wollenberg			
*	4,640,835	02/02/1987	Shimizu, et al.			
*	4,670,417	07/02/1987	Iwaski			
*	4,677,195	06/30/1987	Hewick, et al			
*	4,703,008	10/27/1987	Lin, et al			
*	4,791,192	12/13/1988	Nakagawa			
*	5,061,786	10/29/1991	Burnier			
*	5,106,954	04/21/1992	Fibi, et al			
*	5,143,854	09/01/1992	Pirrung, et al			
*	5,270,170	12/14/1993	Schatz, et al			
*	5,278,065	01/11/1994	D'Andrea			
*	5,322,837	06/21/1994	Hewick, et al			
*	5,369,014	11/29/1994	Brugnara, et al			
*	5,399,551	03/21/1995	Ise, et al			
*	5,424,186	06/13/1995	Fodor, et al			
*	5,432,018	07/11/1995	Dower, et al			
*	5,482,924	01/09/1996	Roy, et al			
*	5,770,358	06/23/1998	Dower, et al			
*	5,767,078	06/16/1998	Johnson et al			
*	5,773,569	06/30/1998	Wrighton, et al			
*	5,830,851	11/16/1998	Wrighton, et al			
*	5,986,047	11/29/1999	Wrighton, et al			

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 44368-0005 C1	SERIAL NO. 10/737,245
	APPLICANT Palani Balu	
	FILING DATE 12/15/2003	GROUP 1656

FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
*	AU 712713	12/30/1996	Australia			<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	CA 2,021,528	01/23/1991	Canada			<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	EP 0428267	05/22/1991	EP			<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	EP 0427189	05/15/1991	EP			<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	EP 0148605	07/17/1985	EP			<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 90/15070	12/1990				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 90/08822	08/09/1990				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 91/05867	05/22/1991				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 93/23550	11/25/1993				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 93/25221	12/23/1993				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 94/02611	02/03/1994				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 95/11987	05/04/1995				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 95/25746	09/28/1995				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 96/40749	12/19/1996				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 96/40772	12/19/1996				<input checked="" type="checkbox"/>	<input type="checkbox"/>
*	WO 01/38342	05/31/2001				<input checked="" type="checkbox"/>	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 44368-0005 C1	SERIAL NO. 10/737,245
	APPLICANT Palani Balu	
	FILING DATE 12/15/2003	GROUP 1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
*	Amagnostou, et al., "Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells", Proc. Natl. Acad. Sci. USA 87: 5978-5982, (1990)
*	Ando, et al., "Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells", Proc. Natl. Acad. Sci. USA 90: 9571-9575, (1993)
*	Balasubramanian, et al., "A Potent synthetic Dimeric agonist of the Erythropoietin Receptor", Peptides: Frontiers of Peptide Science, Proceedings of the 15 th American Peptide Symposium, 1696-1699, (1997)
*	Barker, et al., "Cyclic RGD Peptide Analogues as antiplatelet Antithrombotics", J. Med. Chem. 35: 2040-2048, (1992)
*	Bodonsky, et al., "Active Esters and Resins in Peptide Synthesis", Chem. Ind. 38:1597, (1996)
*	Bowie, et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science 247:1306-1310, (1990)
*	Branch, et al., "Identification of an Erythropoietin Sensitive Cell Line", Blood 69:1782-1785, (1987)
*	Caras, et al., "Signal Peptide for Protein Secretion Directing Glycophospholip Membran Anchor Attachment", Science 243:1196-1198, (1989)
*	Claus-Walker, et al., "Spinal Cord injury and Serum Erythropoietin", Arch. Phys. Med. Rehabil. 65:370-374, (1984)
*	Cotes, et al., "Changes in serum immunoreactive erythropoietin during the menstrual cycle and normal pregnancy", Brit. J. Obstetrics and Gynaecology, 90:305-311, (1983)
*	Cwirla, et al., "Peptides on phage: A vast library of peptides for identifying ligands", Proc. Nat. Acad. Sci. USA 87:6378-6382, (1990)
*	Dainak, et al., "Mechanisms of Abnormal Erythropoiesis in malignancy", Cancer 5, 1101-1106, (1983)
*	Dexter, et al., "Growth of Factor-Dependent Hematopoietic Precursor Cell Lines", J. Exp. Med. 152:1036-1047, (1980)
*	Dower, et al., "The search for Molecular Diversity (II): Recombinant and synthetic randomized Peptide libraries: Ann. Rep. Med. Chem. 26:271-280, (1991)
*	Dunn, et al., "Serum Erythropoietin Titers During Prolonged Bedrest: Relevance to the "Anaemia" of space flight", Eur. J. Appl. Physiol. 52: 178-182, (1984)
*	Dusanter-Fourt, et al., "Erythropoietin induces the tyrosine Phosphorylation of its own receptor in human Erythropoietin-responsive cells", J. Biol. Chem. 267:10670-10678, (1992)
*	Eschbach, et al., "Correction of the Anemia of End-Stage Renal Disease with Recombinant human erythropoietin", N. Eng. J. Med. 316: 73-78, (1987)
*	Fodor, et al., "Light-Directed, Spatially addressable parallel chemical synthesis", Science, 251:767-773, (1991)
*	Graber, et al., "Erythropoietin and the control of red cell production", Ann. Rev. Med., 29:51-66, (1978)

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 44368-0005 C1	SERIAL NO. 10/737,245
	APPLICANT Palani Balu	
	FILING DATE 12/15/2003	GROUP 1656

*	Greenberger, et al., "Demonstration of permanent factor-dependent multipotential erythroid/neutrophil/basophil) hematopoietic progenitor cell lines", Proc. Natl. Acad. Sci. US 80:2931-2935, (1983)
*	Haga, et al., "Plasma Erythropoietin Concentrations during the early Anemia of Prematurity", Acta Paediatr. Scand., 72: 827-831, (1983)
*	Kaiho, et al., "Sensitive Assay Systems for Detection of Hemoglobin with 2,7-Diaminofluorence: Histochemistry and Colorimetry for Erythrodifferentiation", Anal. Biochem. 149:177-120, (1985)
*	Kitamura, et al., "Identification and Analysis of Human Erythropoietin Receptors on a Faactor-Dependent Cell Line, TF-1", Blood 73(2):375-280, (1989)
*	Krantz, et al., "Specific Binding of Erythropoietin to spleen cells infected with the anemia Strain of friend virus", Proc. Natl. Acad. Sci. USA 81:7574-7578, (1984)
*	Krystal, Gerald "A Simple microassay for Erythropoietin based on H-thymidine Incorporation into Spleen calls from Phenylhydrazine Treated Mice", Exp. Hematol., 11(7):649-660, (1983)
*	Konishi, et al., "Trophic effect of Erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro in vivo", Brain Res., 609: 29-35, (1993)
*	Landschulz, et al., "Erythropoietin receptors on murine erythroid colony-forming units: Natural History", Blood 73: 1476-1478, (1989)
*	Leonard, et al., "Dynamics of GATA Transcript factor expression during erythroid differentiation", Blood, 82: 1071-1079, (1993)
*	Lin, et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form", Science, 249:677-679, (1990)
*	Lipschitz, et al., "Effect of Age Hematopoiesis in Man", Blood, 63:502-509, (1983)
*	Livnah, et al., "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The Structure of the EPOR complex to 2.8 Å", Science 273:464-471, (1996)
*	Mayeux, et al., "Murine erythroleukaemia cells (Friend cells) possess high-affinity binding sites for erythropoietin", FEBS Lett., 211: 229-233, (1987)
*	Merrifield "Solid Phase Peptide Synthesis. The Synthesis of a Teterapeptide", J. Am. Chem. Soc., 85:2149, (1963)
*	Miller, et al., "Plasma Levels of Immunoreactive Erythropoietin after acute blood loss in man", Brit. J. Haematol., 52: 545-590, (1982)
*	Morgan and Gainor, et al., "Approaches to the discovery of non-peptide ligands for peptide receptors and peptidases", Ann. Rep. Med. Chem., 24:243-252, (1989)
*	Mosmann "Rapid Colorimetric Assay for cellular growth and survival: Application to Proliferation and Cytotoxicity Assays", J. Immunol. Methods, 65:55, (1983)
*	Mufson, et al., "Binding and Internalization of recombinant Human erythropoietin in Murine erythroid Precursors Cells", Blood, 69:1485-1490, (1987)
*	Yat Su, et al., "Cysteine Alkylation in unprotected peptides: Synthesis of a Carbavasopressin analogue by Intramolecular Cysteine Alkylation", J. Org. Chem., 56:3146-3149, (1991)

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 44368-0005 C1	SERIAL NO. 10/737,245
	APPLICANT Palani Balu	
	FILING DATE 12/15/2003	GROUP 1656

*	Patel, et al., "Activation of two discrete signaling pathways by erythropoietin", J. boil. chem., 267:21300-21302, (1992)
*	Pietta and Marshall, "Amide Protection and Amide supports in solid-phase peptide synthesis", Chem. Comm., 650
*	Quelle, et al., Interleukin 3, Granulocyte Macrophage Colony-stimulating Factor, and Transfected Erythropoietin receptors mediate tyrosine phosphorylation of a common cytosolic protein (pp 100) in FDC-ER Cells", j. Biol. Chem., 267:17055-17060, (1992)
*	Quelle, et al., "Proliferative action of erythropoietin is associated with rapid protein tyrosine phosphorylation in responsive B6Sut.EP", J. Biol. Chem., 266:609-614, (1991)
*	Sakaguchi, et al., "The Expression of Functional Erythropoietin receptors on an Interleukin-3 dependent Cell line", Biochem. biophys. Res. Commun., 146:7-12, (1987)
*	Sasaki, et al., "Carbohydrate Structure of Erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA", J. Biol. Chem., 262:12059-12076, 1987
*	Sawyer, et al., "Identification of the receptor for erythropoietin by cross-linking to friend virus-infected erythroid cells", Proc. Natl. Acad. Sci. USA, 84:3690-3694, 1987
*	Sawyer, et al., "Binding and receptor-mediated endocytosis of erythropoietin in friend virus-infected erythroid cells", J. Biol. Chem., 262:5554-5562, 1987
*	Schwartz, et al., "Severe Anemia as a manifestation of metastatic jugular paraganglioma", Arch. Otolaryngol. 109:269-272, 1983
*	Stewart, et al., solid Phase peptide synthesis pierce chemical co., Rockford, III, Table of Contents
*	Todokoro, et al., "Specific binding of erythropoietin to its receptor on responsive mouse erythroleukemic cells", Proc. Natl. Acad. Sci. USA, 84:4126-4130, 1988
*	Udupa, et al., "Erythropoiesis in the aged mouse", J. Lab.Clin. Med., 103:581-588, 1984
*	Vedovato, et al., "Erythropoietin levels in heterozygous beta-thalassemia", Acta. Haematol., 71:211-213, 1984
*	Vichinsky, et al., "Inadequate erythroid response to hypoxia in cystic fibrosis", J. Pediatric., 105:15-21, 1984
*	Weinstein, et al., Peptide backbone modifications: A structure-activity analysis of peptides containing amide bond surrogates, conformational constraints, and related modifications, Chemistry & Biochemistry of amino Acids, Peptides and Proteins Marcel-Dekker: New York, 7:267
*	Wells, et al., "Hormone Mimicry", Science, 273:449-450, (1996)
*	Willhuhn, et al., "JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with Erythropoietin", Cell, 74:227-236, (1993)
*	Worthington, et al., "Quantitation of Erythroid Differentiation in vitro using a sensitive colorimetric assay for Hemoglobin", Exp. Hematol., 15:85-92, 1987
*	Wrighton, et al., "Small peptides as potent mimics of the protein hormone erythropoietin", Science, 458-464, (1996)
*	Wrighton, et al., "Increased Potency of an erythropoietin peptide mimetic through covalent dimerization", Nature Biotechnology, 15:1261-1265, (1997)
EXAMINER	
DATE CONSIDERED	